News
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...
Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...
Vertex said on Tuesday that its next-generation drug gained European Commission approval for treating cystic fibrosis, a rare ...
VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...
Stocktwits on MSN14h
Vertex Pharma’s New Cystic Fibrosis Drug Granted Approval By EUVertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...
StockStory.org on MSN4d
5 Revealing Analyst Questions From Royalty Pharma’s Q1 Earnings CallRoyalty Pharma’s first quarter reflected a stable performance, with revenue in line with Wall Street expectations and ...
Vertex Pharmaceuticals secured EU approval for ALYFTREK, a next-gen cystic fibrosis therapy boasting a better efficacy ...
Irish Independent on MSN6d
Revenues at cystic fibrosis drugmaker Vertex hit $2.63bn on back of Kaftrio salesSales of the ground-breaking cystic fibrosis (CF) drug Kaftrio was the main driver behind revenues of a Dublin unit of Vertex ...
In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...
A high-level overview of Vertex Pharmaceuticals Incorporated (VRTX) stock. View (VRTX) real-time stock price, chart, news, analysis, analyst reviews and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback